Collaborative To Assess Point-of-Care Manufacturing for Cancer Cell Therapies
Complete the form below to unlock access to ALL audio articles.
Lonza has announced a series of collaborations to exhibit the proprietary Cocoon® Platform’s ability to manufacture novel cell therapies in a decentralized setting. The collaborations include tech transferring cell therapy manufacturing processes developed independently at the Stanford University School of Medicine, Fred Hutchinson Cancer Research Center, and Parker Institute for Cancer Immunotherapy into the Cocoon platform. These leading institutions will evaluate the Cocoon® Platform’s potential to manufacture a range of unique cell therapies.
The Cocoon® Platform is an automated patient-scale cell therapy manufacturing platform. The flexibility to execute a wide variety of protocols within a single system is enabled through a single-use, highly customizable cassette and custom programming.
Process development along with other related activities will be collaboratively shared between each partner and Lonza’s research and development site in Shady Grove (MD), USA. The overarching shared goal is to exhibit the Cocoon® Platform’s capability to manufacture cellular immunotherapies comparable to those produced currently. At the same time, the platform aims to deliver significant benefits including increase process control, reductions in costs, manpower, time and space requirements as well as offering superior scalability, enabling treatment of larger patient populations.
The use of automated manufacturing systems will be a crucial element for academic-clinical centers seeking to succeed as a Point-of-Care manufacturing for patient-scale cell therapies. Each collaborating partner will utilize the Cocoon® Platform to assess the system’s automation, flexibility, and scalability.